Fluorescence Lifetime Imaging Ophthalmoscopy: A Novel Way to Assess Macular Telangiectasia Type 2.

Purpose Macular Telangiectasia Type 2 (MacTel) is an uncommon, late-onset complex retinal disease that leads to central vision loss. No causative gene(s) have been identified so far, resulting in a challenging clinical diagnostic dilemma because retinal changes of early stages are often subtle. The objective of this study was to investigate the benefit of fluorescence lifetime imaging ophthalmoscopy (FLIO) for retinal imaging in patients with MacTel. Design Cross-sectional study from a tertiary-care retinal referral practice. Subjects and Controls 42 eyes of 21 patients (mean age 60.5±13.3 years) with MacTel as well as an age-matched healthy control group (42 eyes of 25 subjects, mean age 60.8±13.4 years). Methods A 30° retinal field centered at the fovea was investigated using FLIO. This camera is based on a Heidelberg Engineering Spectralis system. Fundus autofluorescence (FAF) decays were detected in short (498-560 nm, SSC) and long (560-720 nm, LSC) spectral channels. The mean fluorescence lifetime, τm, was calculated from a 3-exponential approximation of the FAF decays. For MacTel patients, macular pigment (MP), OCT, blue light reflectance, fluorescein angiography, as well as fundus photography, were also recorded. Main Outcome Measures Mean FAF lifetime (τm) images. Results FLIO of MacTel patients shows a unique pattern of prolonged τm at the temporal side of the fovea in patients with MacTel in the "MacTel area" within 5-6° of the foveal center. In early stages, this region appears crescent-shaped, while advanced stages show a ring-like pattern. This pattern corresponds well with other imaging modalities and gives an especially high contrast of the affected region even in minimally affected individuals. Additionally, FLIO provides a novel means to monitor the abnormal MP distribution. In one case, FLIO showed changes suggestive of MacTel within a clinically normal parent of two MacTel patients. Conclusions FLIO detects retinal changes in patients with MacTel with high contrast, presenting a distinctive signature that is a characteristic finding of the disease. The non-invasive properties of this novel imaging modality provide a valuable addition to clinical assessment of early changes in the disease that could lead to more accurate diagnosis of MacTel.

[1]  Tunde Peto,et al.  The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. , 2008, Investigative ophthalmology & visual science.

[2]  Catherine Egan,et al.  "En face" OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia. , 2012, Investigative ophthalmology & visual science.

[3]  Philip J Rosenfeld,et al.  BEVACIZUMAB (AVASTIN) THERAPY FOR IDIOPATHIC MACULAR TELANGIECTASIA TYPE II , 2009, Retina.

[4]  D. Pauleikhoff,et al.  IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2: DISTRIBUTION OF MACULAR PIGMENT AND FUNCTIONAL INVESTIGATIONS , 2010, Retina.

[5]  J. F. Arevalo,et al.  Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2). , 2013, Survey of ophthalmology.

[6]  Daniel Barthelmes,et al.  Differential optical densities of intraretinal spaces. , 2008, Investigative ophthalmology & visual science.

[7]  S. Wolf,et al.  Autofluorescence Lifetimes in Patients With Choroideremia Identify Photoreceptors in Areas With Retinal Pigment Epithelium Atrophy. , 2016, Investigative ophthalmology & visual science.

[8]  Tunde Peto,et al.  Analysis of candidate genes for macular telangiectasia type 2 , 2010, Molecular vision.

[9]  Binxing Li,et al.  Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease , 2016, Progress in Retinal and Eye Research.

[10]  F. Davidorf,et al.  Juxtafoveal telangiectasis-a name change? , 2004, Retina.

[11]  Meidong Zhu,et al.  Loss of Müller's cells and photoreceptors in macular telangiectasia type 2. , 2013, Ophthalmology.

[12]  Werner Gellermann,et al.  MACULAR PIGMENT DISTRIBUTION RESPONSES TO HIGH-DOSE ZEAXANTHIN SUPPLEMENTATION IN PATIENTS WITH MACULAR TELANGIECTASIA TYPE 2 , 2017, Retina.

[13]  D. Schweitzer,et al.  Towards metabolic mapping of the human retina , 2007, Microscopy research and technique.

[14]  Denise Cunningham,et al.  Fundus autofluorescence in type 2 idiopathic macular telangiectasia: correlation with optical coherence tomography and microperimetry. , 2009, American journal of ophthalmology.

[15]  Emily Y. Chew,et al.  Macular telangiectasia type 2 , 2013, Progress in Retinal and Eye Research.

[16]  Hendrik P N Scholl,et al.  Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2. , 2009, Investigative ophthalmology & visual science.

[17]  David Williams,et al.  Retinal crystals in type 2 idiopathic macular telangiectasia. , 2010, Ophthalmology.

[18]  Sebastian Wolf,et al.  Autofluorescence Lifetimes in Geographic Atrophy in Patients With Age-Related Macular Degeneration. , 2016, Investigative ophthalmology & visual science.

[19]  Irene Leung,et al.  MULTIMODAL IMAGING IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA , 2015, Retina.

[20]  M. T. Bonanomi,et al.  Idiopathic Juxtafoveolar Retinal Telangiectasis: Clinical Pattern in 19 Cases , 2000, Ophthalmologica.

[21]  Hendrik P N Scholl,et al.  Familial asymptomatic macular telangiectasia type 2. , 2009, Ophthalmology.

[22]  Dietrich Schweitzer,et al.  Impact of Macular Pigment on Fundus Autofluorescence Lifetimes. , 2015, Investigative ophthalmology & visual science.

[23]  S. Wolf,et al.  Fluorescence Lifetime Imaging in Stargardt Disease: Potential Marker for Disease Progression. , 2016, Investigative ophthalmology & visual science.

[24]  Steffen Schmitz-Valckenberg,et al.  Outer retinal hyperreflective spots on spectral-domain optical coherence tomography in macular telangiectasia type 2. , 2010, Ophthalmology.

[25]  Catherine Egan,et al.  The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia. , 2012, Investigative ophthalmology & visual science.

[26]  Irene Leung,et al.  The Prevalence of Type 2 Idiopathic Macular Telangiectasia in Two African Populations , 2012, Ophthalmic epidemiology.

[27]  Martin Friedlander,et al.  CNTF Attenuates Vasoproliferative Changes Through Upregulation of SOCS3 in a Mouse-Model of Oxygen-Induced Retinopathy , 2016, Investigative ophthalmology & visual science.

[28]  Gwénolé Quellec,et al.  Quantitative analysis of fluorescence lifetime measurements of the macula using the fluorescence lifetime imaging ophthalmoscope in healthy subjects. , 2014, Investigative ophthalmology & visual science.

[29]  D. Schweitzer,et al.  In vivo measurement of time-resolved autofluorescence at the human fundus. , 2004, Journal of biomedical optics.

[30]  R. Guymer,et al.  Perifoveal müller cell depletion in a case of macular telangiectasia type 2. , 2010, Ophthalmology.

[31]  H. Scholl,et al.  ABNORMAL MACULAR PIGMENT DISTRIBUTION IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA , 2008, Retina.

[32]  Sebastian Wolf,et al.  FUNDUS AUTOFLUORESCENCE LIFETIMES AND CENTRAL SEROUS CHORIORETINOPATHY , 2017, Retina.

[33]  Tunde Peto,et al.  Baseline Characteristics of Participants in the Natural History Study of Macular Telangiectasia (MacTel) MacTel Project Report No. 2 , 2010, Ophthalmic epidemiology.

[34]  E. Chew,et al.  Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial. , 2015, American journal of ophthalmology.

[35]  A. Bird,et al.  Macular pigment parameters in patients with macular telangiectasia (MacTel) and normal subjects: implications of a novel analysis. , 2012, Investigative ophthalmology & visual science.

[36]  Sebastian Wolf,et al.  Fluorescence Lifetimes of Drusen in Age-Related Macular Degeneration. , 2017, Investigative ophthalmology & visual science.

[37]  Dietrich Schweitzer,et al.  Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer's disease , 2015, Acta ophthalmologica.

[38]  S A Burns,et al.  Macular pigment density measured by autofluorescence spectrometry: comparison with reflectometry and heterochromatic flicker photometry. , 2001, Journal of the Optical Society of America. A, Optics, image science, and vision.

[39]  A. Khan,et al.  MACULAR TELANGIECTASIA TYPE 2 IN AN OTHERWISE HEALTHY TEENAGE BOY WITH CONSANGUINEOUS PARENTS , 2016, Retinal cases & brief reports.

[40]  M. Hammer,et al.  Fluorescence lifetime imaging ophthalmoscopy , 2017, Progress in Retinal and Eye Research.

[41]  Paolo Carpineto,et al.  Multimodal Imaging of Macular Telangiectasia Type 2: Focus on Vascular Changes Using Optical Coherence Tomography Angiography. , 2016, Investigative ophthalmology & visual science.

[42]  Lien Delaere,et al.  Vertical transmission of macular telangiectasia type 2. , 2012, Retinal cases & brief reports.

[43]  P. Charbel Issa,et al.  Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia. , 2007, Investigative ophthalmology & visual science.

[44]  Ronald Klein,et al.  The prevalence of macular telangiectasia type 2 in the Beaver Dam eye study. , 2010, American journal of ophthalmology.

[45]  Michael D Abramoff,et al.  INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF PROLIFERATIVE AND NONPROLIFERATIVE TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA , 2011, Retina.

[46]  Irene Leung,et al.  Is indocyanine green angiography useful for the diagnosis of macular telangiectasia type 2? , 2013, British Journal of Ophthalmology.

[47]  D. Schweitzer,et al.  Repeatability of Autofluorescence Lifetime Imaging at the Human Fundus in Healthy Volunteers , 2013, Current eye research.

[48]  Krzysztof Kiryluk,et al.  Identification of a Potential Susceptibility Locus for Macular Telangiectasia Type 2 , 2012, PloS one.

[49]  Dietrich Schweitzer,et al.  Monitoring macular pigment changes in macular holes using fluorescence lifetime imaging ophthalmoscopy , 2017, Acta ophthalmologica.

[50]  Martin Hammer,et al.  Fluorescence lifetime imaging ophthalmoscopy in type 2 diabetic patients who have no signs of diabetic retinopathy , 2015, Journal of biomedical optics.

[51]  T. Peto,et al.  ASSOCIATIONS BETWEEN AUTOFLUORESCENCE ABNORMALITIES AND VISUAL ACUITY IN IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2: MacTel Project Report Number 5 , 2014, Retina.

[52]  D. Schweitzer,et al.  Fundus autofluorescence lifetimes are increased in non‐proliferative diabetic retinopathy , 2017, Acta ophthalmologica.

[53]  Melanie Bahlo,et al.  Genome-wide analyses identify common variants associated with macular telangiectasia type 2 , 2017, Nature Genetics.

[54]  Dawn A Sim,et al.  Natural history and effect of therapeutic interventions on subretinal fluid causing foveal detachment in macular telangiectasia type 2 , 2016, British Journal of Ophthalmology.

[55]  Robert J Zawadzki,et al.  Staging of macular telangiectasia: power-Doppler optical coherence tomography and macular pigment optical density. , 2013, Investigative ophthalmology & visual science.

[56]  Irene Leung,et al.  CORRELATION OF CLINICAL AND STRUCTURAL PROGRESSION WITH VISUAL ACUITY LOSS IN MACULAR TELANGIECTASIA TYPE 2: MacTel Project Report No. 6–The MacTel Research Group , 2017, Retina.

[57]  V. Gabel,et al.  Optical coherence tomography findings in idiopathic juxtafoveal retinal telangiectasis , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[58]  B. Blodi,et al.  Idiopathic juxtafoveolar retinal telangiectasis , 1993 .

[59]  J. S. McCasland,et al.  Metabolic Mapping , 2000, Current protocols in neuroscience.

[60]  Dietrich Schweitzer,et al.  Monitoring foveal sparing in geographic atrophy with fluorescence lifetime imaging ophthalmoscopy – a novel approach , 2018, Acta ophthalmologica.

[61]  Frank G. Holz,et al.  Metamorphopsia in patients with macular telangiectasia type 2 , 2009, Documenta Ophthalmologica.

[62]  Binxing Li,et al.  Retinal accumulation of zeaxanthin, lutein, and &bgr;‐carotene in mice deficient in carotenoid cleavage enzymes , 2017, Experimental eye research.

[63]  Dietrich Schweitzer,et al.  FLIMX: A Software Package to Determine and Analyze the Fluorescence Lifetime in Time-Resolved Fluorescence Data from the Human Eye , 2015, PloS one.

[64]  Sebastian Wolf,et al.  Fluorescence lifetime imaging in retinal artery occlusion. , 2015, Investigative ophthalmology & visual science.